Base Therapeutics (shanghai) Co., Ltd.

This early-phase trial tests a new cell therapy called NK521 for people with advanced liver cancer (hepatocellular carcinoma) or ovarian cancer that has not responded to standard treatments. NK521 are natural killer (NK) cells that have been gene-edited to remove three proteins t…

This early-phase trial will test NK510, a cell therapy, in 15 people with advanced stomach or colorectal cancer that has come back or not responded to at least two prior treatments. NK510 is given through an IV or directly into the abdomen. The main goals are to check safety and …